SARAH ALLISON WALL MD
Prescription History 1174815708
Internal Medicine - Hematology in Columbus, OH


Quality Rating: 95.31 out of 100 score

NPI Status: Active since May 16, 2011

Contact Information

460 W 10TH AVE
COLUMBUS, OH
ZIP 43210
Phone: (614) 293-3196
Fax: (614) 293-4812

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SARAH ALLISON WALL MD, an active Hematology specialist practicing in Columbus, OH. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 252 documented patient claims. Among these therapy options, the most frequently utilized medication is Jakafi, which accounts for 128 claims alone.

Medication Index


Iclusig

Generic Formulation: Ponatinib HclSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
OH State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.8
Peer Average Days Supply384
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $225,816.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,528.77

State Avg Cost Per Claim

$25,132.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ponatinib is used to treat certain types of blood cancer (chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
OH State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.1
Peer Average Days Supply685
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $68,906.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,593.76

State Avg Cost Per Claim

$2,905.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology
Provider Metrics Summary
Total Claims 128
30-Day Fills 128.0
Days Supply 3,840
OH State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.4
Peer Average Days Supply758
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 412.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,219,484.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,339.73

State Avg Cost Per Claim

$16,386.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Rezurock

Generic Formulation: Belumosudil MesylateSpecialty: Hematology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 630
OH State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply579
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $457,731.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,805.99

State Avg Cost Per Claim

$23,719.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Belumosudil is used to treat a certain problem that may occur after a stem cell transplant (chronic graft-versus-host disease). Belumosudil belongs to a class of drugs known as kinase inhibitors. It works by blocking some of your immune system's responses which may cause swelling and scarring of certain organs or parts of the body.

Scemblix

Generic Formulation: Asciminib HydrochlorideSpecialty: Hematology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
OH State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$19,192.50

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematology
Provider Metrics Summary
Total Claims 19
30-Day Fills 29.3
Days Supply 732
OH State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply494
Conservative Utilization

This provider writes prescriptions for this formulation 32.1% less frequently than the standard regional baseline metric for practitioners inside OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $158.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.36

State Avg Cost Per Claim

$5.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
OH State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.7
Peer Average Days Supply408
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $195,477.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,770.64

State Avg Cost Per Claim

$15,353.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Vonjo

Generic Formulation: Pacritinib CitrateSpecialty: Hematology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,020
OH State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply510
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for OH. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $801,671.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$23,578.56

State Avg Cost Per Claim

$21,480.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain bone marrow disorder (myelofibrosis). It works by blocking your body from producing substances called growth factors. Pacritinib belongs to a class of drugs known as kinase inhibitors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SARAH ALLISON WALL MD provides transparency into local medical care patterns within Columbus, OH.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.